
Camurus Investor Relations Material
Latest events

Q2 2025
Camurus
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Camurus
Access all reports
Camurus AB is a pharmaceutical company developing and commercializing medicines for severe and chronic conditions. Camurus AB's product portfolio includes PRADAXA, which is indicated for the reduction of the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation; TYSABRI for multiple sclerosis (MS) and psoriatic arthritis; DIFICID for antibiotic-associated diarrhea (AAD); EURAX for ulcerative colitis; and ORAPAVAN for nephrotic syndrome. Camurus AB is based in Lund, Sweden.
Key slides for Camurus
Latest articles
)
The Fifteenth Generation: A Conversation with Pietro Gussalli Beretta
An interview with Pietro Gussalli Beretta on how Beretta Holding blends 500 years of tradition with global growth, innovation, and long-term vision.
10 Jul 2025
)
Citadel: Relentless Optimization at Global Scale
From a Harvard dorm to global dominance, this is the story of how Ken Griffin created one of the best-performing hedge funds of all time.
4 Jul 2025
)
David A. Ricks: Eli Lilly's Chairman and CEO
David Ricks built a decades-long career at Eli Lilly, now leading the giant company through a defining moment in its long pharmaceutical history.
3 Jul 2025
Ticker symbol
CAMX
Country
🇸🇪 Sweden